Program
Anti-CD79b Antibody-drug Conjugate SHR-A1912
Also written as “SHR-A1912; R-Chemo”, “SHR-A1912 Injection” and “SHR-A1912”.
In Jiangsu HengRui Medicine’s pipeline, CD79b ADC
. Its studies are mostly in Lymphoma, B-Cell · Lymphoma, Large B-Cell, Diffuse, led by Jiangsu HengRui Medicine.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Jiangsu HengRui Medicine | 33 open or running | phase 3since Apr 8, 2025 | Nov 5, 2021 | Mar 2027phase 3 · NCT06929624 |
- Named in Jiangsu HengRui Medicine’s own pipeline as
SHR-A1912
, phase 3, as of Jul 31, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Nov 5, 2021First study: phase 1 study in Lymphoma, B-CellFirst studyNCT05113069 · 170 planned · China
- Oct 23, 2023Phase 2 study in Lymphoma, B-CellNCT06104553 · 132 planned · China
- Apr 8, 2025Phase 3 study in Lymphoma, Large B-Cell, DiffuseNCT06929624 · 282 enrolled · China
Ahead
- Mar 2027Primary completion: phase 3 study in Lymphoma, Large B-Cell, DiffuseNCT06929624
TargetBeta
“CD79b ADC”the company's pipeline, read by Claude · source
“An antibody-drug conjugate (ADC) composed of a monoclonal antibody against the tumor-associated antigen (TAA) B-cell antigen receptor complex-associated protein beta chain (CD79b; B-cell-specific glycoprotein B29) conjugated to a topoisomerase-1 inhibitor, with potential antineoplastic activity. …”NCIt, read by Claude
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06929624Lymphoma, Large B-Cell, Diffuse · China | 3 | Active, not recruiting | Mar 2027 | 282 |
| NCT06104553Lymphoma, B-Cell · China | 2 | Recruiting | Dec 2025 | 132 |
| NCT05113069Lymphoma, B-Cell · China | 1 | By invitation | Mar 31, 2024 | 170 |
How it is read
Names in the registry
- “SHR-A1912; R-Chemo”, 2 entries
- “SHR-A1912 Injection”, 1 entry
- “SHR-A1912”, 1 entry
Conditions, from the studies’ own filings
- Lymphoma, B-Cell, 2 studies
- Lymphoma, Large B-Cell, Diffuse, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.